Indispensable roles of OX40L-derived signal and epistatic genetic effect in immune-mediated pathogenesis of spontaneous pulmonary hypertension

详细信息    查看全文

• 作者：Moloud Rabieyousefi (1)
  Pejman Soroosh (2) (7)
  Kimio Satoh (3)
  Fumiko Date (1)
  Naoto Ishii (2) (6)
  Masahiro Yamashita (1)
  Masahiko Oka (4)
  Ivan F McMurtry (4)
  Hiroaki Shimokawa (3)
  Masato Nose (5)
  Kazuo Sugamura (2)
  Masao Ono (1) (6)
  
• 刊名：BMC Immunology
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：12
• 期：1
• 全文大小：627KB
• 参考文献：1. Veeraraghavan S, Koss MN, Sharma OP: Pulmonary veno-occlusive disease. / Curr Opin Pulm Med 1999,5(5):310鈥?13. CrossRef
  2. Dorfmuller P, Perros F, Balabanian K, Humbert M: Inflammation in pulmonary arterial hypertension. / Eur Respir J 2003,22(2):358鈥?63. CrossRef
  3. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, / et al.: Cellular and molecular pathobiology of pulmonary arterial hypertension. / J Am Coll Cardiol 2004,43(12 Suppl S):13S-24S. CrossRef
  4. Golembeski SM, West J, Tada Y, Fagan KA: Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. / Chest 2005,128(6 Suppl):572S-573S. CrossRef
  5. Hoshino T, Kato S, Oka N, Imaoka H, Kinoshita T, Takei S, Kitasato Y, Kawayama T, Imaizumi T, Yamada K, / et al.: Pulmonary Inflammation and Emphysema: Role of the Cytokines IL-18 and IL-13. / Am J Respir Crit Care Med 2007,176(1):49鈥?2. CrossRef
  6. Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF: Autoimmunity and pulmonary hypertension: a perspective. / Eur Respir J 2005,26(6):1110鈥?118. CrossRef
  7. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, Scerbavicius R, Burns N, Cool C, Wood K, Parr JE, Boackle SA, Voelkel NF: Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. / Am J Respir Crit Care Med 2007,175(12):1280鈥?289. CrossRef
  8. Lenschow DJ, Walunas TL, Bluestone JA: CD28/B7 system of T cell costimulation. / Annu Rev Immunol 1996, 14:233鈥?58. CrossRef
  9. Croft M: Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? / Nat Rev Immunol 2003,3(8):609鈥?20. CrossRef
  10. Sugamura K, Ishii N, Weinberg AD: Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. / Nat Rev Immunol 2004,4(6):420鈥?31. CrossRef
  11. Mestas J, Crampton SP, Hori T, Hughes CC: Endothelial cell co-stimulation through OX40 augments and prolongs T cell cytokine synthesis by stabilization of cytokine mRNA. / Int Immunol 2005,17(6):737鈥?47. CrossRef
  12. Kotani A, Hori T, Matsumura Y, Uchiyama T: Signaling of gp34 (OX40 ligand) induces vascular endothelial cells to produce a CC chemokine RANTES/CCL5. / Immunol Lett 2002,84(1):1鈥?. CrossRef
  13. Gramaglia I, Weinberg AD, Lemon M, Croft M: Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. / J Immunol 1998,161(12):6510鈥?517.
  14. Murata K, Ishii N, Takano H, Miura S, Ndhlovu LC, Nose M, Noda T, Sugamura K: Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. / J Exp Med 2000,191(2):365鈥?74. CrossRef
  15. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M: OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. / Immunity 2001,15(3):445鈥?55. CrossRef
  16. Soroosh P, Ine S, Sugamura K, Ishii N: OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity. / J Immunol 2006,176(10):5975鈥?987.
  17. Soroosh P, Ine S, Sugamura K, Ishii N: Differential Requirements for OX40 Signals on Generation of Effector and Central Memory CD4+ T Cells. / J Immunol 2007,179(8):5014鈥?023.
  18. Maxwell JR, Weinberg A, Prell RA, Vella AT: Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. / J Immunol 2000,164(1):107鈥?12.
  19. Murata K, Nose M, Ndhlovu LC, Sato T, Sugamura K, Ishii N: Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. / J Immunol 2002,169(8):4628鈥?636.
  20. Satoh K, Kagaya Y, Nakano M, Ito Y, Ohta J, Tada H, Karibe A, Minegishi N, Suzuki N, Yamamoto M, / et al.: Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. / Circulation 2006,113(11):1442鈥?450. CrossRef
  21. Marzo AL, Vezys V, Williams K, Tough DF, Lefrancois L: Tissue-level regulation of Th1 and Th2 primary and memory CD4 T cells in response to Listeria infection. / J Immunol 2002,168(9):4504鈥?510.
  22. Lander E, Kruglyak L: Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. / Nat Genet 1995,11(3):241鈥?47. CrossRef
  23. Morris JA, Gardner MJ: Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. / Br Med J (Clin Res Ed) 1988,296(6632):1313鈥?316. CrossRef
  24. Sakaguchi S: Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. / Annu Rev Immunol 2004, 22:531鈥?62. CrossRef
  25. Hadeiba H, Locksley RM: Lung CD25 CD4 regulatory T cells suppress type 2 immune responses but not bronchial hyperreactivity. / J Immunol 2003,170(11):5502鈥?510.
  26. Lewkowich IP, Herman NS, Schleifer KW, Dance MP, Chen BL, Dienger KM, Sproles AA, Shah JS, Kohl J, Belkaid Y, / et al.: CD4+CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. / J Exp Med 2005,202(11):1549鈥?561. CrossRef
  27. McKinley L, Logar AJ, McAllister F, Zheng M, Steele C, Kolls JK: Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia. / J Immunol 2006,177(9):6215鈥?226.
  28. Bodolay E, Csipo I, Gal I, Sipka S, Gyimesi E, Szekanecz Z, Szegedi G: Anti-endothelial cell antibodies in mixed connective tissue disease: frequency and association with clinical symptoms. / Clin Exp Rheumatol 2004,22(4):409鈥?15.
  29. Vegh J, Szodoray P, Kappelmayer J, Csipo I, Udvardy M, Lakos G, Aleksza M, Soltesz P, Szilagyi A, Zeher M, / et al.: Clinical and immunoserological characteristics of mixed connective tissue disease associated with pulmonary arterial hypertension. / Scand J Immunol 2006,64(1):69鈥?6. CrossRef
  30. Wang X, Ria M, Kelmenson PM, Eriksson P, Higgins DC, Samnegard A, Petros C, Rollins J, Bennet AM, Wiman B, / et al.: Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. / Nat Genet 2005,37(4):365鈥?72. CrossRef
  31. van Wanrooij EJ, van Puijvelde GH, de Vos P, Yagita H, van Berkel TJ, Kuiper J: Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. / Arterioscler Thromb Vasc Biol 2007,27(1):204鈥?10. CrossRef
  32. Takeda I, Ine S, Killeen N, Ndhlovu LC, Murata K, Satomi S, Sugamura K, Ishii N: Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. / J Immunol 2004,172(6):3580鈥?589.
  33. Ohshima Y, Yang LP, Uchiyama T, Tanaka Y, Baum P, Sergerie M, Hermann P, Delespesse G: OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. / Blood 1998,92(9):3338鈥?345.
  34. Hoshino A, Tanaka Y, Akiba H, Asakura Y, Mita Y, Sakurai T, Takaoka A, Nakaike S, Ishii N, Sugamura K, / et al.: Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma. / Eur J Immunol 2003,33(4):861鈥?69. CrossRef
  35. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y: IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. / Proc Natl Acad Sci USA 2003,100(10):5986鈥?990. CrossRef
  36. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, / et al.: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. / J Clin Invest 1999,103(9):1345鈥?352. CrossRef
  37. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y: Increased expression of interleukin 17 in inflammatory bowel disease. / Gut 2003,52(1):65鈥?0. CrossRef
  38. Zhu Z, Ma B, Zheng T, Homer RJ, Lee CG, Charo IF, Noble P, Elias JA: IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. / J Immunol 2002,168(6):2953鈥?962.
  39. Daley E, Emson C, Guignabert C, de Waal Malefyt R, Louten J, Kurup VP, Hogaboam C, Taraseviciene-Stewart L, Voelkel NF, Rabinovitch M, / et al.: Pulmonary arterial remodeling induced by a Th2 immune response. / J Exp Med 2008,205(2):361鈥?72. CrossRef
  40. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, / et al.: Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. / Am J Hum Genet 2000,67(3):737鈥?44. CrossRef
  41. Morse JH, Deng Z, Knowles JA: Genetic aspects of pulmonary arterial hypertension. / Ann Med 2001,33(9):596鈥?03. CrossRef
  42. Quinlan TR, Li D, Laubach VE, Shesely EG, Zhou N, Johns RA: eNOS-deficient mice show reduced pulmonary vascular proliferation and remodeling to chronic hypoxia. / Am J Physiol Lung Cell Mol Physiol 2000,279(4):L641鈥?50.
  43. Steudel W, Scherrer-Crosbie M, Bloch KD, Weimann J, Huang PL, Jones RC, Picard MH, Zapol WM: Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3. / J Clin Invest 1998,101(11):2468鈥?477. CrossRef
  44. Droma Y, Hanaoka M, Ota M, Katsuyama Y, Koizumi T, Fujimoto K, Kobayashi T, Kubo K: Positive association of the endothelial nitric oxide synthase gene polymorphisms with high-altitude pulmonary edema. / Circulation 2002,106(7):826鈥?30. CrossRef
  45. Ono M, Sawa Y, Mizuno S, Fukushima N, Ichikawa H, Bessho K, Nakamura T, Matsuda H: Hepatocyte growth factor suppresses vascular medial hyperplasia and matrix accumulation in advanced pulmonary hypertension of rats. / Circulation 2004,110(18):2896鈥?902. CrossRef
  46. Ito W, Kanehiro A, Matsumoto K, Hirano A, Ono K, Maruyama H, Kataoka M, Nakamura T, Gelfand EW, Tanimoto M: Hepatocyte growth factor attenuates airway hyperresponsiveness, inflammation, and remodeling. / Am J Respir Cell Mol Biol 2005,32(4):268鈥?80. CrossRef
  47. Niedbala W, Wei XQ, Campbell C, Thomson D, Komai-Koma M, Liew FY: Nitric oxide preferentially induces type 1 T cell differentiation by selectively up-regulating IL-12 receptor beta 2 expression via cGMP. / Proc Natl Acad Sci USA 2002,99(25):16186鈥?6191. CrossRef
  48. Ivy DD, McMurtry IF, Colvin K, Imamura M, Oka M, Lee DS, Gebb S, Jones PL: Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptor-deficient rats: a new model of severe pulmonary arterial hypertension. / Circulation 2005,111(22):2988鈥?996. CrossRef
  
• 作者单位：Moloud Rabieyousefi (1)
  Pejman Soroosh (2) (7)
  Kimio Satoh (3)
  Fumiko Date (1)
  Naoto Ishii (2) (6)
  Masahiro Yamashita (1)
  Masahiko Oka (4)
  Ivan F McMurtry (4)
  Hiroaki Shimokawa (3)
  Masato Nose (5)
  Kazuo Sugamura (2)
  Masao Ono (1) (6)
  
  1. Department of Pathology, Tohoku University Graduate School of Medicine, 2-1 Seiryo, Aoba-ku, Sendai, Miyagi, 980-8575, Japan
  2. Department of Immunology, Tohoku University Graduate School of Medicine, 2-1 Seiryo, Aoba-ku, Sendai, Miyagi, 980-8575, Japan
  7. Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 3210 Merryfield Row, San Diego, California, 92121, USA
  3. Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 2-1 Seiryo, Aoba-ku, Sendai, Miyagi, 980-8575, Japan
  6. Japan Science and Technology Agency, CREST, Tokyo, Japan
  4. Department of Pharmacology and Medicine and Center for Lung Biology, University of South Alabama, College of Medicine, 307 University Blvd N Mobile, AL, Kragujevac, 36688-0002, USA
  5. Department of Pathology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan
  
• ISSN：1471-2172

文摘

Background Pulmonary hypertension (PH) refers to a spectrum of diseases with elevated pulmonary artery pressure. Pulmonary arterial hypertension (PAH) is a disease category that clinically presents with severe PH and that is histopathologically characterized by the occlusion of pulmonary arterioles, medial muscular hypertrophy, and/or intimal fibrosis. PAH occurs with a secondary as well as a primary onset. Secondary PAH is known to be complicated with immunological disorders. The aim of the present study is to histopathologically and genetically characterize a new animal model of PAH and clarify the role of OX40 ligand in the pathogenesis of PAH. Results Spontaneous onset of PAH was stably identified in mice with immune abnormality because of overexpression of the tumor necrosis factor (TNF) family molecule OX40 ligand (OX40L). Histopathological and physical examinations revealed the onset of PAH-like disorders in the C57BL/6 (B6) strain of OX40L transgenic mice (B6.TgL). Comparative analysis performed using different strains of transgenic mice showed that this onset depends on the presence of OX40L in the B6 genetic background. Genetic analyses demonstrated a susceptibility locus of a B6 allele to this onset on chromosome 5. Immunological analyses revealed that the excessive OX40 signals in TgL mice attenuates expansion of regulatory T cells the B6 genetic background, suggesting an impact of the B6 genetic background on the differentiation of regulatory T cells. Conclusion Present findings suggest a role for the OX40L-derived immune response and epistatic genetic effect in immune-mediated pathogenesis of PAH.